Lab testing continues to be an integral part of care delivery, but regulatory changes have negatively impacted reimbursement.  With the stabilization in reimbursement resulting from the first round of PAMA, we’re seeing an increase in transactions in this sector.  Consolidation continued in the first quarter as established participants sought to build market share, and provider-based and independent labs looked for ways to streamline costs and improve cash flow generation.